Why Zynerba Pharmaceuticals Stock Is Jumping Today

What happened

Shares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) were up 6.3% as of 11:03 a.m. EDT on Tuesday after rising as much as 11.5% earlier in the session. The gains appear to be the result of Roth Capital analyst Jerry Isaacson initiating coverage of Zynerba with a buy rating and a price target of $36, which reflected a 211% premium above the stock's closing price on Monday.

So what

One analyst's positive opinion on Zynerba isn't all that significant in the grand scheme of things. However, it is important for investors to understand what's behind the optimism.

Scientists in lab looking at a beaker with green fluid

Image source: Getty Images.

Zynerba's lead pipeline candidate is Zygel, a cannabidiol (CBD) gel that's being evaluated in a phase 3 clinical study for treating Fragile X syndrome (FXS). Roth Capital's Isaacson, though, thinks that there are even bigger opportunities for Zygel in other indications.

The biotech currently has three phase 2 clinical studies of Zygel under way. One is evaluating the CBD drug in treating developmental and epileptic encephalopathies (DEE), which include rare and ultra-rare epilepsy syndromes where patients can experience seizures, behavioral disturbances, and brain electrical activity abnormalities. The other phase 2 studies focus on autism spectrum disorders in pediatric patients and adult refractory focal epilepsy.

In addition, Zynerba plans to initiate another phase 2 study in the second quarter. This study will evaluate Zygel in treating 22q deletion syndrome, the most common gene deletion syndrome, affecting up to 81,000 patients in the U.S.

Now what

The main thing to watch now is how Zygel performs in clinical studies. Zynerba anticipates reporting top-line data from the pivotal FXS study later this year. If all goes well, the biotech could file for U.S. regulatory approval for Zygel in the FXS indication in the first half of 2020.

Results from Zynerba's phase 2 studies shouldn't be too far off, either. The company expects to announce top-line data through week 26 from the DEE study in the third quarter of 2019. Zynerba should report results from its 22q study in the first half of 2020.

10 stocks we like better than Zynerba Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynerba Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 1, 2019

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Personal Finance , Stocks
Referenced Symbols: CBD , FXS , ZYNE

More from Motley Fool


Motley Fool

Motley Fool

Market News, Investing

Research Brokers before you trade

Want to trade FX?